These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 26754826)

  • 21. [Hypomethylating agents for the treatment of myelodysplastic syndromes].
    Itzykson R; Fenaux P
    Bull Cancer; 2011 Aug; 98(8):927-34. PubMed ID: 21821482
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Azacitidine and the beginnings of therapeutic epigenetic modulation.
    O'Dwyer K; Maslak P
    Expert Opin Pharmacother; 2008 Aug; 9(11):1981-6. PubMed ID: 18627335
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Response to 5-azacytidine in a patient with relapsed Hodgkin Lymphoma and a therapy-related myelodysplastic syndrome.
    D'Alò F; Leone G; Hohaus S; Teofili L; Bozzoli V; Tisi MC; Rufini V; Calcagni ML; Voso MT
    Br J Haematol; 2011 Jul; 154(1):141-3. PubMed ID: 21332703
    [No Abstract]   [Full Text] [Related]  

  • 24. Newly proposed therapy-related myelodysplastic syndrome prognostic score predicts significant differences in overall survival and leukemia-free survival in patients treated with azacitidine.
    Breccia M; Fianchi L; Lunghi M; Gaidano G; Levis A; Finelli C; Santini V; Musto P; Mansueto G; Oliva EN; Leoni P; Spiriti MA; Hohaus S; Leone G; Alimena G; Voso MT
    Leuk Lymphoma; 2013 Aug; 54(8):1786-7. PubMed ID: 23151268
    [No Abstract]   [Full Text] [Related]  

  • 25. Sequential azacitidine and lenalidomide in patients with high-risk myelodysplastic syndromes and acute myeloid leukaemia: a single-arm, phase 1/2 study.
    DiNardo CD; Daver N; Jabbour E; Kadia T; Borthakur G; Konopleva M; Pemmaraju N; Yang H; Pierce S; Wierda W; Bueso-Ramos C; Patel KP; Cortes JE; Ravandi F; Kantarjian HM; Garcia-Manero G
    Lancet Haematol; 2015 Jan; 2(1):e12-20. PubMed ID: 26687423
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy, safety, and pharmacokinetics of subcutaneous azacitidine in Taiwanese patients with higher-risk myelodysplastic syndromes.
    Chou WC; Yeh SP; Hsiao LT; Lin SF; Chen YC; Chen TY; Laille E; Galettis A; Dong Q; Songer S; Beach CL
    Asia Pac J Clin Oncol; 2017 Oct; 13(5):e430-e439. PubMed ID: 28124500
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Azacitidine.
    Issa JP; Kantarjian H
    Nat Rev Drug Discov; 2005 May; Suppl():S6-7. PubMed ID: 15962522
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Successful treatment of donor cell derived myelodysplastic syndrome with 5-azacytidine.
    Jennane S; El Haddad M; Mahtat EM; Doghmi K; Mikdame M
    Ann Biol Clin (Paris); 2017 Dec; 75(6):713-714. PubMed ID: 29043987
    [No Abstract]   [Full Text] [Related]  

  • 29. [The clinical research of treatment by decitabine moderate or high-risk myelodysplastic syndrome patients].
    Shao XR; Liang H; Guan XJ
    Zhonghua Xue Ye Xue Za Zhi; 2011 Nov; 32(11):789-91. PubMed ID: 22339920
    [No Abstract]   [Full Text] [Related]  

  • 30. Myelodysplastic syndromes (MDS).
    Klimek V
    Best Pract Res Clin Haematol; 2015 Mar; 28(1):1-2. PubMed ID: 25659724
    [No Abstract]   [Full Text] [Related]  

  • 31. Drug therapy for myelodysplastic syndrome: building evidence for action.
    Tefferi A; Letendre L
    Cancer; 2006 Apr; 106(8):1650-2. PubMed ID: 16532501
    [No Abstract]   [Full Text] [Related]  

  • 32. Obstacles to adherence to azacitidine administration schedule in outpatient myelodysplastic syndrome and related disorders.
    Tendas A; Lissia MF; Piccioni D; Tirimbelli L; Scaramucci L; Giovannini M; Dentamaro T; Perrotti A; de Fabritiis P; Niscola P
    Support Care Cancer; 2015 Feb; 23(2):303-5. PubMed ID: 25370894
    [No Abstract]   [Full Text] [Related]  

  • 33. New therapeutic approaches in myelodysplastic syndromes: Hypomethylating agents and lenalidomide.
    Loiseau C; Ali A; Itzykson R
    Exp Hematol; 2015 Aug; 43(8):661-72. PubMed ID: 26123365
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Minimizing risk of hypomethylating agent failure in patients with higher-risk MDS and practical management recommendations.
    Santini V; Prebet T; Fenaux P; Gattermann N; Nilsson L; Pfeilstöcker M; Vyas P; List AF
    Leuk Res; 2014 Dec; 38(12):1381-91. PubMed ID: 25444075
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Predicting outcome of patients with myelodysplastic syndromes after failure of azacitidine: validation of the North American MDS consortium scoring system.
    Prebet T; Fenaux P; Vey N;
    Haematologica; 2016 Oct; 101(10):e427-e428. PubMed ID: 27694503
    [No Abstract]   [Full Text] [Related]  

  • 36. Decitabine in myelodysplastic syndromes: viewpoints.
    Garcia-Manero G; Saba HI
    Drugs; 2006; 66(7):959-60. PubMed ID: 16740015
    [No Abstract]   [Full Text] [Related]  

  • 37. Myelodysplasia, megakaryocytes, and methylation.
    Steensma DP
    Leuk Res; 2004 Aug; 28(8):775-6. PubMed ID: 15203274
    [No Abstract]   [Full Text] [Related]  

  • 38. Dismal outcome of acute myeloid leukemia secondary to myelodysplastic syndrome and chronic myelomonocytic leukemia after azacitidine failure in a daily-life setting.
    Niscola P; Tendas A; Cupelli L; Giovannini M; Piccioni D; Scaramucci L; Dentamaro T; Del Poeta G; de Fabritiis P
    Acta Haematol; 2015; 133(1):64-6. PubMed ID: 25139255
    [No Abstract]   [Full Text] [Related]  

  • 39. Phase I and II study of azacitidine in Japanese patients with myelodysplastic syndromes.
    Uchida T; Ogawa Y; Kobayashi Y; Ishikawa T; Ohashi H; Hata T; Usui N; Taniwaki M; Ohnishi K; Akiyama H; Ozawa K; Ohyashiki K; Okamoto S; Tomita A; Nakao S; Tobinai K; Ogura M; Ando K; Hotta T
    Cancer Sci; 2011 Sep; 102(9):1680-6. PubMed ID: 21624006
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The revised IPSS is a powerful tool to evaluate the outcome of MDS patients treated with azacitidine: the GFM experience.
    Lamarque M; Raynaud S; Itzykson R; Thepot S; Quesnel B; Dreyfus F; Rauzy OB; Turlure P; Vey N; Recher C; Dartigeas C; Legros L; Delaunay J; Visanica S; Stamatoullas A; Fenaux P; Adès L
    Blood; 2012 Dec; 120(25):5084-5. PubMed ID: 23243156
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.